HER2 Testing, Adjuvant Trastuzumab Use and Results. Our Experience in South Wales

Clinical Oncology

Volumn 22, Issue 10, 2010, Pages 894-

  Webster, R ^a   Palaniappan, N ^a   Abraham, J ^a   Bertelli, G ^b   Jasani, B ^c   Barrett Lee, P ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

^b South West Wales Cancer Institute ^*  (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; DISEASE FREE SURVIVAL; EARLY CANCER; HEART FUNCTION; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR BIOPSY; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2; WALES;

EID: 78149501187     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.07.003     Document Type: Letter

References (5)

1. Coulson S.G., Kumar V.S., Kumar I.M., et al. Review of testing and use of adjuvant trazuzumab across a cancer network - are we treating the right patients?. Clin Oncol 2010, 22:289-293.
2. Nielsen D.L., Andersson M., Kamby C., et al. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35:121-136.
3. Sauter G., Lee J., Bartlett J.M., et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009, 27:1323-1333.
4. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
5. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.